Key takeaways
- Drugs@FDA lists no product containing MOTS-c, 21 CFR 216.23 does not list it, and FDA staff found no USP or NF monograph for it (18 Nov 2026).
- MOTS-c sat in FDA’s compounding Category 2 from 29 September 2023 to 22 April 2026; HHS records that “neither the placement nor the removal changed its status under section 503A”.
- FDA’s category list of 14 May 2026 places MOTS-c in none of its three categories, and FDA’s safety-risk page says compounded MOTS-c “may pose significant risk for immunogenicity for certain routes of administration”.
- HHS’s October 2026 enforcement-discretion policy names MOTS-c among six peptides; the Federal Register notice calls it a draft that “is not binding on HHS or the public”.
- HHS says the policy is meant to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients”.
01Is MOTS-c an approved drug in the US?
No. We found no US law that names MOTS-c. Its status comes from the drug provisions of the Federal Food, Drug, and Cosmetic Act.
No approval. Drugs@FDA, queried through openFDA for MOTS-c as an active ingredient, returned no matches on 18 November 2026; the same query for tirzepatide returned two applications. FDA staff, reviewing MOTS-c for the July 2026 advisory committee, wrote: “MOTS-c and MOTS-c acetate do not have an applicable USP or NF drug substance monograph and neither is a component of an FDA-approved drug.”
Unapproved new drugs. FDA’s warning letters to online peptide sellers set out the rule: “a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect”. They also show how FDA reads research labels. One dated 24 August 2026 says: “Despite statements on your product labeling marketing your products for ‘research use only’ and ‘not for human consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.” The twelve letters we read, dated December 2025 to August 2026, do not name MOTS-c. More: what “research use only” means.
Not a controlled substance. MOTS-c does not appear in the federal controlled-substance schedules, 21 CFR Part 1308 (eCFR, 16 November 2026). For MOTS-c the live questions are drug law and compounding policy, not drug scheduling.
02Can US pharmacies compound MOTS-c?
MOTS-c is not on the statute’s list of bulk ingredients. A draft HHS policy published in October 2026 covers licensed compounders who use it, under conditions.
The statute. Under section 503A, a state-licensed pharmacy, federal facility or licensed physician compounds from bulk ingredients that meet a USP or NF monograph, belong to an FDA-approved drug, or appear on the 503A bulks list. MOTS-c has no monograph and no approved product, and 21 CFR 216.23(a) lists six substances, none of them MOTS-c (eCFR, 16 November 2026).
FDA’s categories. While the list is built, FDA sorts nominated substances into interim categories. HHS records that MOTS-c “was in Category 2 from September 29, 2023, until April 22, 2026, and neither the placement nor the removal changed its status under section 503A”. FDA’s list of nominated substances, updated 14 May 2026, places it in none of its three categories. FDA’s safety-risk page lists “MOTs-C” among Category 2 substances whose nominations “were withdrawn by the nominators”, and keeps its entry: “Compounded drugs containing MOTs-C may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization.” Immunogenicity is the tendency to provoke an immune response. Mechanics: FDA peptide categories.
The HHS policy. HHS’s “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” lists MOTS-c in Appendix A, with BPC-157, epitalon, KPV, Semax and TB-500. Until each is addressed in a final rule, HHS “does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician” compounding one of them when ten conditions are all present. They include an FDA-registered original manufacturer and a certificate of analysis, reporting of serious adverse events to FDA, one active ingredient per product, the label “This is a compounded drug product. Not for resale.” and a patient-specific prescription. HHS “may revisit” the policy if “a safety signal or product quality issue arises”. Detail: the HHS policy explained.
What it is not. The Federal Register notice calls it a draft that “does not establish any rights for any person and is not binding on HHS or the public.” It is not an approval, and it adds nothing to the bulks list. HHS says the policy is meant to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients.”
03What did FDA’s 2026 review of MOTS-c find?
The review behind the July 2026 committee vote. FDA staff and HHS read the same record differently, so both are here.
FDA staff. The briefing for FDA’s Pharmacy Compounding Advisory Committee found MOTS-c acetate “not well-characterized” from a physical and chemical perspective. It found “a lack of evidence to evaluate the effectiveness” for the uses nominated, and concluded that “potential safety risks associated with the use of MOTS-c in humans are unknown”. It found no published study in which drug products containing MOTS-c were used in people. On balance, FDA staff wrote, these points “weigh against their being added to the 503A Bulks List.”
The committee. The committee discussed MOTS-c on 23 July 2026 and, HHS records, voted in favour of listing it, against the recommendation of FDA’s drug centre (CDER). FDA says advisory committees “make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.” The vote: the July 2026 panel.
HHS. HHS’s appendix says “the available safety evidence points in one direction”, citing a randomised placebo-controlled trial of an unnamed MOTS-c analogue that “reported no serious adverse events”. An analogue is a different molecule, and FDA says it has not identified any human exposure data on drug products containing MOTS-c. The research record: MOTS-c claims and the evidence.
04What has changed for MOTS-c in the US, and when?
The status steps, in order. Some websites describe April 2026 as a move toward Category 1 that opened MOTS-c to pharmacy compounding. FDA’s May list places MOTS-c in no category, and HHS says the April removal did not change its status.
| Date | What happened | Source |
|---|---|---|
| 29 Sep 2023 | MOTS-c is placed in Category 2, bulk substances that raise significant safety risks | HHS Appendix B |
| 16 Apr 2026 | FDA gives notice of a 23–24 July meeting of its compounding advisory committee, with MOTS-c on the agenda | Federal Register 2026-07361 |
| 22 Apr 2026 | MOTS-c leaves Category 2 after its nominations are withdrawn; FDA’s safety-risk page lists it as withdrawn, with its risk entry | HHS Appendix B; FDA safety-risk page |
| 14 May 2026 | FDA’s updated category list places MOTS-c in none of its three categories | FDA category list |
| 23 Jul 2026 | The committee discusses MOTS-c; CDER recommends against listing, and the committee votes in favour | FDA meeting page; HHS Appendix B |
| 28 Oct 2026 | HHS’s notice of its enforcement-discretion policy, with MOTS-c in Appendix A, is filed with the Federal Register | Federal Register filing line |
| 30 Oct 2026 | The notice is published (91 FR 68526), with comments invited for two weeks | Federal Register |
| 18 Nov 2026 | No proposed rule on the 503A bulks list has appeared since 1 July 2026 | Federal Register search |
Every change is logged in our regulatory changelog.
05How is MOTS-c treated in US sport?
Anti-doping rules are set separately from US drug law. WADA’s Prohibited List names MOTS-c in class S4.4.1, metabolic modulators, prohibited in and out of competition. USADA says it is “explicitly listed”, and: “It is highly unlikely an athlete would get a TUE approved for MOTS-c because there is no approved therapeutic use for this experimental drug.” USADA also tells athletes to be “extremely wary” of experimental peptides, MOTS-c among them, sold with “for research purposes only” labels or in compounded medications. Detail: is MOTS-c banned in sport?
06What we don’t know about MOTS-c in the US
- Whether FDA will propose adding MOTS-c to the 503A bulks list, and when. No proposed rule had appeared by 18 November 2026.
- How long the HHS policy will last. It runs until each peptide is addressed in a final rule, unless HHS revisits it earlier.
- How FDA would treat a particular MOTS-c product. Intended use is judged from the whole sale, product by product.
- State rules. State boards license prescribers and pharmacies and have issued their own statements on peptides: are peptides legal in the US?
The compound itself: our MOTS-c research guide.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.